Most Read

Led by Deerfield Management, the funding round saw participation from existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform backed by KKR,

Initially executed in 2017, the agreement grants exclusive rights to Kyowa Kirin for the development and commercialisation of Ardelyx’s tenapanor to treat cardiorenal diseases including hyperphosphatemia in Japan.

The clinical trial is designed for assessing GRC 54276’s tolerability and safety as a monotherapy, as well as in combination with checkpoint inhibitors in these patients. GRC 54276

HBM7022 has been produced from HBM’s HCAb Based Immune Cell Engagers (HBICE) Platform. It crosslinks tumour and T cells by targeting a tumour-associated antigen (Claudin18.2) and CD3 that

A kinase inhibitor, vijoice is intended for the treatment of rare overgrowth conditions which are caused by the effects of PIK3CA mutations in adults and children aged two

Upon receiving approval, the human monoclonal antibody Dupixent will be the first medicine available in the US for the treatment of eosinophilic esophagitis (EoE). It is designed to

A recombinant humanized IgG4 monoclonal antibody, TAB009/JS009 is developed against human CD112R to treat advanced malignant tumours. CD112R, also known as Poliovirus receptor-related immunoglobulin domain-containing protein (PVRIG), is

Under the deal, Organon will obtain global rights to FDA-approved Xaciato, which is intended to treat bacterial vaginosis (BV) in females aged 12 years and above. The vaginal

The company filed the NDA with the Department of Health in the Hong Kong Special Administrative Region. The SG drug is a first-in-class Trop-2 directed antibody-drug conjugate and